+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Brucella Abortus Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2035

  • PDF Icon

    Report

  • 150 Pages
  • November 2026
  • Region: Global
  • Lucintel
  • ID: 6293482
The global brucella abortus vaccine market is expected to reach an estimated $589 million by 2035 from $372 million in 2027 with a CAGR of 7.9% from 2027 to 2035. The major drivers for this market are the rising incidence of brucellosis, growing awareness of zoonotic diseases, and increase demand in livestock farming.

The future of the global brucella abortus vaccine market looks promising with opportunities in the cattle's, sheep, pigs vend others markets.
  • Within the type category, DNA vaccines is expected to witness the highest growth over the forecast period due to the growing need for safer, needle-free DNA-based vaccination technology for livestock.
  • Within the application category, cattle's is expected to witness the highest growth over the forecast period due to brucellosis affects the livestock industry, particularly cattle farming and the production of dairy.
  • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to Asia has a big cattle population and an increasing number of vaccination programs for livestock.

Emerging Trends in Brucella Abortus Vaccine Market

The market for the Brucella abortus vaccine is moving from reactive, herd-based treatment to prevention built on surveillance, differentiated vaccine strains, and traceable vaccine delivery. It is expected that from 2025 to 2027, demand will be influenced by cattle intensification and national Brucellosis eradication programs, as well as export requirements and the control of zoonotic Brucellosis. According to Lucintel, veterinary biologics and regional disease control budgets will be the primary growth drivers.
  • Implementation of Scheduled Herd Immunizations: In 2025, scheduled coverage will replace emergency response for procurement of vaccines in national immunization campaigns and the prioritization of S19 and RB51. A vaccination control model with recurring demand will be established, as governments continue to link vaccination to testing and cattle movement.
  • Control with DIVA: During the period of 2025 to 2027, testing along with immunization and serology, with confirmation by PCR, will be done in order to differentiate vaccinated from infected animals. The control will help avoid false positives during the certification for trade. The DIVA capability will impact the selection of products for control, since eradication programs require cleaner surveillance data.
  • Improved Stability of Thermostable Vaccines: In 2025, field programs toward immunization of livestock in remote regions of Africa will continue to focus on the development of stable vaccines and cold chain logistics. The vaccine currently requires storage 2-8 °C. Within the next 5 years, improvement in logistics will become a criteria for purchase.
  • Local Manufacture: In the period 2025 to 2027 local manufacture of veterinary biologics will be encouraged by procurement focused on manufacturing and fill-finish as well as technology transfer and establishment of quality standards. This will create a new level of competition for reliable, timely supply, and enhanced national control of livestock disease.
  • One Health Integration: Agencies are starting to connect cattle vaccination with human brucellosis surveillance in 2025, showing the economic burden of zoonotic disease; the WHO estimates 500,000 human cases per year. This connection will shift focus and allocate funding to integrated veterinary-human programs and will increase demand for defined herd-level metrics.
The next phase of the market will not be focused on vaccine availability but rather on the performance of the associated programs. Combinations of strains that are validated, reliable cold-chain support, diagnostic alignment, and field outcomes will be favored. Public procurement will retain its importance; however, private dairy and beef farmers will increasingly pay for vaccinations as a protection against loses of production, disrupted trade, exposure to reputation risk, and disease risk.

Recent Developments in the Brucella Abortus Vaccine Market

Interest in the brucella abortus vaccine is anticipated to grow from 2025 to 2027 as governments link disease control with dairy, trade, and food security programs. While procurement remains in the public sector, vaccine manufacturers are improving their delivery systems and cold-chain logistics. Lucintel predicts that the market will continue growing steadily with the highest demand in countries that implement integrated cattle vaccination programs.
  • National Vaccination Campaigns: Female-calf immunization as part of India's livestock disease control program continued targeting animals that were 4-8 months old (January 2025). This initiative supports continued bulk orders and benefits suppliers that can meet national tenders at low unit cost.
  • Government Procurement Expansion: The animal health arm of Brazil's government continued to enforce the requirement for the brucellosis vaccination of heifers that were 3-8 months old (March 2025). The requirement ensures a first dose. Imposition of schedules for replacement ensures a constant demand for vaccination.
  • Cold-chain Technology Upgrades: Improvements in refrigerated logistics for live Brucella vaccines by veterinary distributors was evident with several national programs requiring storage at 2\-8°C (June 2025). Improved cold-chain technology will discourage field failures and encourage adoption in remote dairy regions over the next 5 years.
  • Diagnostic-linked Control: Disease-control agencies in many countries began to adopt a policy of carrying out more tests on herds to be certified prior to certification and implementing serological surveillance of vaccinated herds (September 2025).
  • Regional Market Access: The African Union and national veterinary services have been working together to continue developing regional plans to control brucellosis in both pastoral and commercial herds. Millions of cattle were vaccinated against brucellosis in 2025 (November 2025). Wider public funding should be able to help break even in new markets, but it is currently the main bottleneck for the commercial sector.
The demand for brucellosis vaccines will remain policy-led, as governments view brucellosis control as an important productivity issue rather than a veterinary issue in its own right. Vaccine suppliers with thermostable brucellosis vaccines, strong field data and economic delivery will win government contracts. Better gains are likely to come through organized dairy systems and government-led campaigns rather than through the private sector. Private sector growth is likely to be more constrained due to surveillance issues and uneven farmer awareness during the next decade.

Strategic Growth Opportunities in the Brucella Abortus Vaccine Market

Market expansion for Brucella abortus vaccines is expected to be robust as livestock traceability, border control trade policies, and productivity goals of herd improvement come into effect in the years 2024 to 2026. According to Lucintel, demand will evolve from traditional vaccination programs to the provision of differentiated formulations and services that assist producers in documenting disease control.
  • Expanding Rural Herd: Beyond government-aided campaigns, private vaccination packages can serve smallholder dairy operations in rural areas. The 2025 livestock health program in India targeted vaccination of 100 million cattle and buffalo (March 2025). In the next 3 to 5 years, increasing commercialization of herd will create a sustained market for veterinary doses.
  • Premium Differentiated Vaccines: Differentiated formulations that require less interference and designed for specific age groups of vaccination can result in higher profits compared to general supply contracts. For 2025, the USDA APHIS confirmed that RB51 can be used for official purposes. There will be a demand for compliant alternatives (February 2025). Farmers will buy vaccines that help in surveillance and retain the right to export.
  • Geographic Expansion: Intensification of dairy in Africa and Central Asia will create new markets, as Brucellosis exposure will increase due to lack of veterinary infrastructure. The FAO stated that livestock sustains 1.3 billion livelihoods (June 2025). In the next 5 years, new market partnerships focused on thermostable vaccines will be created.
  • Digital Vaccination Records: Mobile records linked to ear tags can contain all herd management records, including vaccinations, herd tests, movement permits, and replacement decisions. The 2025 rollout of the European livestock traceability system includes over 24 million animals (January 2025). Subscription-based services utilizing data will result in higher renewal rates compared to one-time vaccine sales.
  • Integrated Control Programs: Large dairy companies can buy vaccine packages that include diagnostics, cold-chain logistics, training, and post-vaccination monitoring from vaccine suppliers. WOAH’s 2025 directive continued to emphasize the importance of coordinated surveillance and vaccination (May 2025). Integrated contracts also shift the customer focus to measurable outcomes of herd health, and purchasing is directed to suppliers with field service.
Commercial risks, rather than the number of animals, will be the primary spending focus for disease control. Export-oriented dairies, breeding farms, and public veterinary services will rely on dependable products supported by traceability and evidence. Suppliers that provide local vaccination registrations, cold-chain logistics, and vaccination surveillance will capture the most significant value. While the tendering process will remain highly competitive, specialized services can allow for an improvement in the profit margin and create lasting accounts.

Brucella Abortus Vaccine Market Drivers and Challenges

Market growth for the Brucella abortus vaccine depends upon the priorities and funds directed toward animal health, growth of livestock, advancements in diagnostics, and public funding. Safety and sustainability concerns, as well as improvements in veterinary services, drive customer demand. However, markets are hampered by inconsistent vaccination programs, cold chain logistics, trade constraints, and uncertainty regarding vaccine efficacy. Lucintel indicates that a greater emphasis on integrated control strategies and the use of new technologies will dominate for the next several years.

The factors responsible for driving this market include:

  • Control of Diseases: Reduced fertility, abortion, and public health concerns coupled with the reduction in milk yield drive national and regional authorities to strengthen the control and eradication of bovine brucellosis. In January 2025, partnered vaccination and surveillance campaigns with the Brucella abortus vaccines were conducted. The activities create a consistent demand from livestock producers and veterinary services. During the next three to five years, it is anticipated that increasing public funding, herd registration, and reporting will stimulate an increase in Brucella abortus vaccine demand in regions with persistent infection. More integration of testing, vaccination, identification, and control of animal movement will enhance the markets and provide growth potential for an extended period.
  • Increase in Livestock Production: Increasing populations of livestock and the consequent increase in the production of both dairy and beef have created a necessity for prevention vaccinations. Producers estimate the cost of preventing diseases becomes less than the cost of dealing with abortions, infertility, and trade losses coupled with the expense of replacing the animals. March of 2025 showed a continued focus by livestock governing bodies on herd-health measures with the expansion of cattle production in developing markets. Large-scale commercial farms usually prioritize scheduled vaccinations since they value both the constant productivity of their livestock as well as biosecurity. For the next three to five years, the demand for both protein and dairy coupled with the introduction of organized farming will create an expanding market. However, the demand will continue to be dependent on the veterinary services available in a country and the policies of the national vaccination program.
  • Positive Legislative Changes: Bovine brucellosis control is furthered by the new regulations and animal health standards of both the public and private sectors alike. More and more authorities associate herd health testing, permits for animal movement, and declarations of no diseases with vaccination records. May 2025 showed the World Organization for Animal Health once again providing incremental changes to their directives aimed at the management of bovine brucellosis. Enhanced approaches and coordination leap positive steps for trading partners, veterinarians, and farmers. Improvements in requirements for traceability and a more active regulatory control system will be positive drivers for approved vaccinations. The field effectiveness and compliance of vaccination safety will be determining factors for new market entrants.
  • Product Innovation: Research is looking into reducing adverse reactions, improving protection across cattle populations, and enhancing diagnostic tools in order to provide complementary tests to distinguish vaccinated from naturally infected animals. Evolution of vaccines in formulations and the ability to adapt methods of delivery with greater stability and convenience of storage to facilitate diagnostic compatibility is improving convenience for administration of vaccinations. Continuing researches in veterinary programs focused on the development of next generation brucellosis vaccines and technologies to differentiate infected from vaccinated animals were conducted during August 2025. More products with longer shelf life, ease of administration, and improved compatibility for vaccinations to support eradication programs are expected to be available in the next three to five years. Innovations may even be able to support vaccination in previously unreachable areas with little to no specialized veterinary services and/or unreliable refrigeration.
  • Expanding Veterinary Infrastructure: Increases in the availability of veterinary services (laboratories) and the development of mobile teams for vaccination combined with improvements for the cold chain for livestock records has improved availability of disease-control products. Digital identification and field-based surveillance was implemented by various livestock health programs in February 2026 to enhance vaccinations and improve response to outbreaks. Along with loss reduction during distribution, the improvement of veterinary services will enable authorities to implement effective compliance programs for animal herd control. The anticipated three to five year outlook for market penetration of veterinary services in developing countries will be improved by expanding rural veterinary services and public/private partnerships. Digital records should help forecast demand for vaccinations, help governments target vaccinations to high-risk cattle, and should reduce the prevalence of counterfeit vaccinations.

The challenges facing this market include:

  • Vaccine Efficacy and Diagnostic Confusion: Some strains of Brucella abortus vaccines present challenges for surveillance, certification, and eradication programs, as vaccinated animals may produce antibodies that mimic an infection response. Consequently, vaccinated animals may test positive for infection. In April 2025, veterinary services continued to recommend integrated vaccination and testing to minimize misclassification. Demand for specialized diagnostic tests and improved vaccines will likely increase over the next three to five years, while diagnostic confusion may slow the adoption of disease-free certification in regions for which it is economically important. Producer and regulatory agencies will continue to request improved monitoring, assurance that vaccination will not impact disease control, and clearer direction.
  • Cold Chain and Distribution Issues: Lack of reliable cold chain, transport, vaccinators, and veterinarians in many areas can lower vaccine potency, increase wastage, and decrease herd vaccine coverage. In July 2025, livestock health services continued to emphasize the importance of distribution of vaccines and biologics in a cold chain, particularly in remote areas. Infrastructure constraints in the next three to five years will dominate issues in new markets. Vaccine manufacturers will need to make thermostable vaccines and formulations intended for use in smaller packaging and remote clinics with better distribution systems. If these issues are not addressed, market growth will remain concentrated in large private farms and more significant public programs in the next three to five years.
  • Funding and Policy Inconsistency: Programs for the control of brucellosis require funds from governments, participation of producers, and a changing prioritization of national goals. In November 2025, animal health departments in multiple regions continued to make revisions to their animal health budgets to address multiple demands for disease control. Inconsistent funding, voluntary vaccination, and changing trade policies create an uneven demand and disrupt multiannual eradication programs. In the next 3 to 5 years, these factors will create challenges for vendors to forecast sales and make an investment to produce locally. A stable funding source, coordinated regulations, and trade policies that compensate affected farmers will ensure sustainability of market growth and development.
The market for the brucellosis vaccines will grow as livestock production, food safety, regulatory, and veterinary services improve. Improvements in disease control will present additional business opportunities, especially in countries that have persistent brucellosis. There will be limitations to market growth because of diagnostic challenges, cold-chain, inconsistent funding, and poorly enforced policies. Vendors that provide reliable vaccines and integrate vaccination, as well as test and delivery services, will experience the most growth. In the next 3 to 5 years, the combination of improved regulation, producer participation, and technology will drive the use of vaccinations as a larger and sustained part of brucellosis control within the global cattle industry.

List of Brucella Abortus Vaccine Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies brucella abortus vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.

Some of the brucella abortus vaccine market companies profiled in this report include:

  • Zoetis
  • Ceva
  • Merck Animal Health
  • Biovet
  • Cavac
  • Jovac
  • Merial
  • Colorado Serum Company
  • Vecol
  • Tecnovax

Brucella Abortus Vaccine Market by Segment

The study includes a forecast for the global brucella abortus vaccine market by type, application, and region.

Type [Value ($B) from 2019 to 2035]:

  • DNA Vaccines
  • Subunit Vaccines
  • Vector Vaccines
  • B. Abortus Recombinant Mutants
  • Others

Application [Value ($B) from 2019 to 2035]:

  • Cattles
  • Sheep
  • Pigs
  • Others

Region [Value ($B) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Brucella Abortus Vaccine Market

The market for brucella abortus vaccine is being influenced by government policies to eradicate diseases, increased livestock surveillance, and public procurement rather than private demand. Between 2025 and 2027, eradication-focused governments will prioritize vaccination in endemic regions and disease-free countries will emphasize testing and control over livestock movement. Based on Lucintel’s newest market research, policy execution will determine the market size in the next five years.
  • United States: Surveillance and Eradication: The USDA APHIS continues to implement the National Brucellosis Program. For the year 2025, APHIS maintained Wyoming’s Class Free Status and continued the Greater Yellowstone Area in enhanced surveillance. This regulatory policy for the special needs area will continue to create demand for the vaccine in the special needs area and will minimize the general area from routine use.
  • China: National Animal Disease Control: In January 2025, the Ministry of Agriculture and Rural Affairs of China included brucellosis in their 2025 National Immunization and Surveillance Schedule and mandated that all groups implement and report the policy. This policy will create a continuous demand by the public sector for the vaccine and encourage the vaccine production in China.
  • Germany: Disease-Free Controls: Germany is bound by the EU Animal Health Law and relies primarily on testing, tracing, and movement controls rather than routine vaccination of cattle. The 2025 Animal Health Framework of the European Commission continues to recognize the officially brucellosis-free territories. This policy will limit large scale vaccinations but will sustain the demand for authorized products in exceptional regional controls.
  • India: Mass bovine immunization: The 2025-26 stage in the implementation of the National Animal Disease Control Programmed aims to vaccinate approximately 50 million female bovines against brucellosis each year, along with other vaccinations for other livestock. The procurement of brucellosis vaccines and mass campaigns make this the strongest public sector demand source in Asia for the next 3 to 5 years.
  • Japan: Surveillance-led eradication: The Ministry of Agriculture, Forestry and Fisheries continued implementing mandatory notifications and movement control as part of the 2025 Livestock Disease Control framework. Brucellosis vaccination is not a routine national policy. The disease-free policy will continue to limit market volumes and will provide an ongoing demand for diagnostic and emergency supplies should brucellosis be introduced.

Features of the Global Brucella Abortus Vaccine Market

  • Market Size Estimates: brucella abortus vaccine market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
  • Segmentation Analysis: brucella abortus vaccine market size by type, application, and region in terms of value ($B).
  • Regional Analysis: brucella abortus vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the brucella abortus vaccine market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the brucella abortus vaccine market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

This report answers the following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the brucella abortus vaccine market by type (DNA vaccines, subunit vaccines, vector vaccines, b. abortus recombinant mutants, and others), application (cattle, sheep, pigs, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
2. Market Overview
2.1 Background and Classifications
2.2 Supply Chain
3. Market Trends & Forecast Analysis
3.1 Global Brucella Abortus Vaccine Market Trends and Forecast
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment
4. Global Brucella Abortus Vaccine Market by Type
4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 DNA Vaccines: Trends and Forecast (2019-2035)
4.4 Subunit Vaccines: Trends and Forecast (2019-2035)
4.5 Vector Vaccines: Trends and Forecast (2019-2035)
4.6 B. Abortus Recombinant Mutants: Trends and Forecast (2019-2035)
4.7 Others: Trends and Forecast (2019-2035)
5. Global Brucella Abortus Vaccine Market by Application
5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Cattles: Trends and Forecast (2019-2035)
5.4 Sheep: Trends and Forecast (2019-2035)
5.5 Pigs: Trends and Forecast (2019-2035)
5.6 Others: Trends and Forecast (2019-2035)
6. Regional Analysis
6.1 Overview
6.2 Global Brucella Abortus Vaccine Market by Region
7. North American Brucella Abortus Vaccine Market
7.1 Overview
7.2 North American Brucella Abortus Vaccine Market by Type
7.3 North American Brucella Abortus Vaccine Market by Application
7.4 United States Brucella Abortus Vaccine Market
7.5 Mexican Brucella Abortus Vaccine Market
7.6 Canadian Brucella Abortus Vaccine Market
8. European Brucella Abortus Vaccine Market
8.1 Overview
8.2 European Brucella Abortus Vaccine Market by Type
8.3 European Brucella Abortus Vaccine Market by Application
8.4 German Brucella Abortus Vaccine Market
8.5 French Brucella Abortus Vaccine Market
8.6 Spanish Brucella Abortus Vaccine Market
8.7 Italian Brucella Abortus Vaccine Market
8.8 United Kingdom Brucella Abortus Vaccine Market
9. APAC Brucella Abortus Vaccine Market
9.1 Overview
9.2 APAC Brucella Abortus Vaccine Market by Type
9.3 APAC Brucella Abortus Vaccine Market by Application
9.4 Japanese Brucella Abortus Vaccine Market
9.5 Indian Brucella Abortus Vaccine Market
9.6 Chinese Brucella Abortus Vaccine Market
9.7 South Korean Brucella Abortus Vaccine Market
9.8 Indonesian Brucella Abortus Vaccine Market
10. RoW Brucella Abortus Vaccine Market
10.1 Overview
10.2 RoW Brucella Abortus Vaccine Market by Type
10.3 RoW Brucella Abortus Vaccine Market by Application
10.4 Middle Eastern Brucella Abortus Vaccine Market
10.5 South American Brucella Abortus Vaccine Market
10.6 African Brucella Abortus Vaccine Market
11. Competitor Analysis
11.1 Product Portfolio Analysis
11.2 Operational Integration
11.3 Porter’s Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
11.4 Market Share Analysis
12. Opportunities & Strategic Analysis
12.1 Value Chain Analysis
12.2 Growth Opportunity Analysis
12.2.1 Growth Opportunities by Type
12.2.2 Growth Opportunities by Application
12.3 Emerging Trends in the Global Brucella Abortus Vaccine Market
12.4 Strategic Analysis
12.4.1 New Product Development
12.4.2 Certification and Licensing
12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures
13. Company Profiles of the Leading Players Across the Value Chain
13.1 Competitive Analysis
13.2 Zoetis
  • Company Overview
  • Brucella Abortus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.3 Ceva
  • Company Overview
  • Brucella Abortus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.4 Merck Animal Health
  • Company Overview
  • Brucella Abortus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.5 Biovet
  • Company Overview
  • Brucella Abortus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.6 Cavac
  • Company Overview
  • Brucella Abortus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.7 Jovac
  • Company Overview
  • Brucella Abortus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.8 Merial
  • Company Overview
  • Brucella Abortus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.9 Colorado Serum Company
  • Company Overview
  • Brucella Abortus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.10 Vecol
  • Company Overview
  • Brucella Abortus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.11 Tecnovax
  • Company Overview
  • Brucella Abortus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
14. Appendix
14.1 List of Figures
14.2 List of Tables
14.3 Research Methodology
14.4 Disclaimer
14.5 Copyright
14.6 Abbreviations and Technical Units
14.7 About Us
14.8 Contact Us
List of Figures
Chapter 1
Figure 1.1: Trends and Forecast for the Global Brucella Abortus Vaccine Market
Chapter 2
Figure 2.1: Usage of Brucella Abortus Vaccine Market
Figure 2.2: Classification of the Global Brucella Abortus Vaccine Market
Figure 2.3: Supply Chain of the Global Brucella Abortus Vaccine Market
Chapter 3
Figure 3.1: Driver and Challenges of the Brucella Abortus Vaccine Market
Figure 3.2: PESTLE Analysis
Figure 3.3: Patent Analysis
Figure 3.4: Regulatory Environment
Chapter 4
Figure 4.1: Global Brucella Abortus Vaccine Market by Type in 2019, 2026, and 2035
Figure 4.2: Trends of the Global Brucella Abortus Vaccine Market ($B) by Type
Figure 4.3: Forecast for the Global Brucella Abortus Vaccine Market ($B) by Type
Figure 4.4: Trends and Forecast for DNA Vaccines in the Global Brucella Abortus Vaccine Market (2019-2035)
Figure 4.5: Trends and Forecast for Subunit Vaccines in the Global Brucella Abortus Vaccine Market (2019-2035)
Figure 4.6: Trends and Forecast for Vector Vaccines in the Global Brucella Abortus Vaccine Market (2019-2035)
Figure 4.7: Trends and Forecast for B. Abortus Recombinant Mutants in the Global Brucella Abortus Vaccine Market (2019-2035)
Figure 4.8: Trends and Forecast for Others in the Global Brucella Abortus Vaccine Market (2019-2035)
Chapter 5
Figure 5.1: Global Brucella Abortus Vaccine Market by Application in 2019, 2026, and 2035
Figure 5.2: Trends of the Global Brucella Abortus Vaccine Market ($B) by Application
Figure 5.3: Forecast for the Global Brucella Abortus Vaccine Market ($B) by Application
Figure 5.4: Trends and Forecast for Cattles in the Global Brucella Abortus Vaccine Market (2019-2035)
Figure 5.5: Trends and Forecast for Sheep in the Global Brucella Abortus Vaccine Market (2019-2035)
Figure 5.6: Trends and Forecast for Pigs in the Global Brucella Abortus Vaccine Market (2019-2035)
Figure 5.7: Trends and Forecast for Others in the Global Brucella Abortus Vaccine Market (2019-2035)
Chapter 6
Figure 6.1: Trends of the Global Brucella Abortus Vaccine Market ($B) by Region (2019-2026)
Figure 6.2: Forecast for the Global Brucella Abortus Vaccine Market ($B) by Region (2027-2035)
Chapter 7
Figure 7.1: North American Brucella Abortus Vaccine Market by Type in 2019, 2026, and 2035
Figure 7.2: Trends of the North American Brucella Abortus Vaccine Market ($B) by Type (2019-2026)
Figure 7.3: Forecast for the North American Brucella Abortus Vaccine Market ($B) by Type (2027-2035)
Figure 7.4: North American Brucella Abortus Vaccine Market by Application in 2019, 2026, and 2035
Figure 7.5: Trends of the North American Brucella Abortus Vaccine Market ($B) by Application (2019-2026)
Figure 7.6: Forecast for the North American Brucella Abortus Vaccine Market ($B) by Application (2027-2035)
Figure 7.7: Trends and Forecast for the United States Brucella Abortus Vaccine Market ($B) (2019-2035)
Figure 7.8: Trends and Forecast for the Mexican Brucella Abortus Vaccine Market ($B) (2019-2035)
Figure 7.9: Trends and Forecast for the Canadian Brucella Abortus Vaccine Market ($B) (2019-2035)
Chapter 8
Figure 8.1: European Brucella Abortus Vaccine Market by Type in 2019, 2026, and 2035
Figure 8.2: Trends of the European Brucella Abortus Vaccine Market ($B) by Type (2019-2026)
Figure 8.3: Forecast for the European Brucella Abortus Vaccine Market ($B) by Type (2027-2035)
Figure 8.4: European Brucella Abortus Vaccine Market by Application in 2019, 2026, and 2035
Figure 8.5: Trends of the European Brucella Abortus Vaccine Market ($B) by Application (2019-2026)
Figure 8.6: Forecast for the European Brucella Abortus Vaccine Market ($B) by Application (2027-2035)
Figure 8.7: Trends and Forecast for the German Brucella Abortus Vaccine Market ($B) (2019-2035)
Figure 8.8: Trends and Forecast for the French Brucella Abortus Vaccine Market ($B) (2019-2035)
Figure 8.9: Trends and Forecast for the Spanish Brucella Abortus Vaccine Market ($B) (2019-2035)
Figure 8.10: Trends and Forecast for the Italian Brucella Abortus Vaccine Market ($B) (2019-2035)
Figure 8.11: Trends and Forecast for the United Kingdom Brucella Abortus Vaccine Market ($B) (2019-2035)
Chapter 9
Figure 9.1: APAC Brucella Abortus Vaccine Market by Type in 2019, 2026, and 2035
Figure 9.2: Trends of the APAC Brucella Abortus Vaccine Market ($B) by Type (2019-2026)
Figure 9.3: Forecast for the APAC Brucella Abortus Vaccine Market ($B) by Type (2027-2035)
Figure 9.4: APAC Brucella Abortus Vaccine Market by Application in 2019, 2026, and 2035
Figure 9.5: Trends of the APAC Brucella Abortus Vaccine Market ($B) by Application (2019-2026)
Figure 9.6: Forecast for the APAC Brucella Abortus Vaccine Market ($B) by Application (2027-2035)
Figure 9.7: Trends and Forecast for the Japanese Brucella Abortus Vaccine Market ($B) (2019-2035)
Figure 9.8: Trends and Forecast for the Indian Brucella Abortus Vaccine Market ($B) (2019-2035)
Figure 9.9: Trends and Forecast for the Chinese Brucella Abortus Vaccine Market ($B) (2019-2035)
Figure 9.10: Trends and Forecast for the South Korean Brucella Abortus Vaccine Market ($B) (2019-2035)
Figure 9.11: Trends and Forecast for the Indonesian Brucella Abortus Vaccine Market ($B) (2019-2035)
Chapter 10
Figure 10.1: RoW Brucella Abortus Vaccine Market by Type in 2019, 2026, and 2035
Figure 10.2: Trends of the RoW Brucella Abortus Vaccine Market ($B) by Type (2019-2026)
Figure 10.3: Forecast for the RoW Brucella Abortus Vaccine Market ($B) by Type (2027-2035)
Figure 10.4: RoW Brucella Abortus Vaccine Market by Application in 2019, 2026, and 2035
Figure 10.5: Trends of the RoW Brucella Abortus Vaccine Market ($B) by Application (2019-2026)
Figure 10.6: Forecast for the RoW Brucella Abortus Vaccine Market ($B) by Application (2027-2035)
Figure 10.7: Trends and Forecast for the Middle Eastern Brucella Abortus Vaccine Market ($B) (2019-2035)
Figure 10.8: Trends and Forecast for the South American Brucella Abortus Vaccine Market ($B) (2019-2035)
Figure 10.9: Trends and Forecast for the African Brucella Abortus Vaccine Market ($B) (2019-2035)
Chapter 11
Figure 11.1: Porter’s Five Forces Analysis of the Global Brucella Abortus Vaccine Market
Figure 11.2: Market Share (%) of Top Players in the Global Brucella Abortus Vaccine Market (2026)
Chapter 12
Figure 12.1: Growth Opportunities for the Global Brucella Abortus Vaccine Market by Type
Figure 12.2: Growth Opportunities for the Global Brucella Abortus Vaccine Market by Application
Figure 12.3: Growth Opportunities for the Global Brucella Abortus Vaccine Market by Region
Figure 12.4: Emerging Trends in the Global Brucella Abortus Vaccine Market
List of Tables
Chapter 1
Table 1.1: Growth Rate (%, 2025-2026) and CAGR (%, 2027-2035) of the Brucella Abortus Vaccine Market by Type and Application
Table 1.2: Attractiveness Analysis for the Brucella Abortus Vaccine Market by Region
Table 1.3: Global Brucella Abortus Vaccine Market Parameters and Attributes
Chapter 3
Table 3.1: Trends of the Global Brucella Abortus Vaccine Market (2019-2026)
Table 3.2: Forecast for the Global Brucella Abortus Vaccine Market (2027-2035)
Chapter 4
Table 4.1: Attractiveness Analysis for the Global Brucella Abortus Vaccine Market by Type
Table 4.2: Market Size and CAGR of Various Type in the Global Brucella Abortus Vaccine Market (2019-2026)
Table 4.3: Market Size and CAGR of Various Type in the Global Brucella Abortus Vaccine Market (2027-2035)
Table 4.4: Trends of DNA Vaccines in the Global Brucella Abortus Vaccine Market (2019-2026)
Table 4.5: Forecast for DNA Vaccines in the Global Brucella Abortus Vaccine Market (2027-2035)
Table 4.6: Trends of Subunit Vaccines in the Global Brucella Abortus Vaccine Market (2019-2026)
Table 4.7: Forecast for Subunit Vaccines in the Global Brucella Abortus Vaccine Market (2027-2035)
Table 4.8: Trends of Vector Vaccines in the Global Brucella Abortus Vaccine Market (2019-2026)
Table 4.9: Forecast for Vector Vaccines in the Global Brucella Abortus Vaccine Market (2027-2035)
Table 4.10: Trends of B. Abortus Recombinant Mutants in the Global Brucella Abortus Vaccine Market (2019-2026)
Table 4.11: Forecast for B. Abortus Recombinant Mutants in the Global Brucella Abortus Vaccine Market (2027-2035)
Table 4.12: Trends of Others in the Global Brucella Abortus Vaccine Market (2019-2026)
Table 4.13: Forecast for Others in the Global Brucella Abortus Vaccine Market (2027-2035)
Chapter 5
Table 5.1: Attractiveness Analysis for the Global Brucella Abortus Vaccine Market by Application
Table 5.2: Market Size and CAGR of Various Application in the Global Brucella Abortus Vaccine Market (2019-2026)
Table 5.3: Market Size and CAGR of Various Application in the Global Brucella Abortus Vaccine Market (2027-2035)
Table 5.4: Trends of Cattles in the Global Brucella Abortus Vaccine Market (2019-2026)
Table 5.5: Forecast for Cattles in the Global Brucella Abortus Vaccine Market (2027-2035)
Table 5.6: Trends of Sheep in the Global Brucella Abortus Vaccine Market (2019-2026)
Table 5.7: Forecast for Sheep in the Global Brucella Abortus Vaccine Market (2027-2035)
Table 5.8: Trends of Pigs in the Global Brucella Abortus Vaccine Market (2019-2026)
Table 5.9: Forecast for Pigs in the Global Brucella Abortus Vaccine Market (2027-2035)
Table 5.10: Trends of Others in the Global Brucella Abortus Vaccine Market (2019-2026)
Table 5.11: Forecast for Others in the Global Brucella Abortus Vaccine Market (2027-2035)
Chapter 6
Table 6.1: Market Size and CAGR of Various Regions in the Global Brucella Abortus Vaccine Market (2019-2026)
Table 6.2: Market Size and CAGR of Various Regions in the Global Brucella Abortus Vaccine Market (2027-2035)
Chapter 7
Table 7.1: Trends of the North American Brucella Abortus Vaccine Market (2019-2026)
Table 7.2: Forecast for the North American Brucella Abortus Vaccine Market (2027-2035)
Table 7.3: Market Size and CAGR of Various Type in the North American Brucella Abortus Vaccine Market (2019-2026)
Table 7.4: Market Size and CAGR of Various Type in the North American Brucella Abortus Vaccine Market (2027-2035)
Table 7.5: Market Size and CAGR of Various Application in the North American Brucella Abortus Vaccine Market (2019-2026)
Table 7.6: Market Size and CAGR of Various Application in the North American Brucella Abortus Vaccine Market (2027-2035)
Table 7.7: Trends and Forecast for the United States Brucella Abortus Vaccine Market (2019-2035)
Table 7.8: Trends and Forecast for the Mexican Brucella Abortus Vaccine Market (2019-2035)
Table 7.9: Trends and Forecast for the Canadian Brucella Abortus Vaccine Market (2019-2035)
Chapter 8
Table 8.1: Trends of the European Brucella Abortus Vaccine Market (2019-2026)
Table 8.2: Forecast for the European Brucella Abortus Vaccine Market (2027-2035)
Table 8.3: Market Size and CAGR of Various Type in the European Brucella Abortus Vaccine Market (2019-2026)
Table 8.4: Market Size and CAGR of Various Type in the European Brucella Abortus Vaccine Market (2027-2035)
Table 8.5: Market Size and CAGR of Various Application in the European Brucella Abortus Vaccine Market (2019-2026)
Table 8.6: Market Size and CAGR of Various Application in the European Brucella Abortus Vaccine Market (2027-2035)
Table 8.7: Trends and Forecast for the German Brucella Abortus Vaccine Market (2019-2035)
Table 8.8: Trends and Forecast for the French Brucella Abortus Vaccine Market (2019-2035)
Table 8.9: Trends and Forecast for the Spanish Brucella Abortus Vaccine Market (2019-2035)
Table 8.10: Trends and Forecast for the Italian Brucella Abortus Vaccine Market (2019-2035)
Table 8.11: Trends and Forecast for the United Kingdom Brucella Abortus Vaccine Market (2019-2035)
Chapter 9
Table 9.1: Trends of the APAC Brucella Abortus Vaccine Market (2019-2026)
Table 9.2: Forecast for the APAC Brucella Abortus Vaccine Market (2027-2035)
Table 9.3: Market Size and CAGR of Various Type in the APAC Brucella Abortus Vaccine Market (2019-2026)
Table 9.4: Market Size and CAGR of Various Type in the APAC Brucella Abortus Vaccine Market (2027-2035)
Table 9.5: Market Size and CAGR of Various Application in the APAC Brucella Abortus Vaccine Market (2019-2026)
Table 9.6: Market Size and CAGR of Various Application in the APAC Brucella Abortus Vaccine Market (2027-2035)
Table 9.7: Trends and Forecast for the Japanese Brucella Abortus Vaccine Market (2019-2035)
Table 9.8: Trends and Forecast for the Indian Brucella Abortus Vaccine Market (2019-2035)
Table 9.9: Trends and Forecast for the Chinese Brucella Abortus Vaccine Market (2019-2035)
Table 9.10: Trends and Forecast for the South Korean Brucella Abortus Vaccine Market (2019-2035)
Table 9.11: Trends and Forecast for the Indonesian Brucella Abortus Vaccine Market (2019-2035)
Chapter 10
Table 10.1: Trends of the RoW Brucella Abortus Vaccine Market (2019-2026)
Table 10.2: Forecast for the RoW Brucella Abortus Vaccine Market (2027-2035)
Table 10.3: Market Size and CAGR of Various Type in the RoW Brucella Abortus Vaccine Market (2019-2026)
Table 10.4: Market Size and CAGR of Various Type in the RoW Brucella Abortus Vaccine Market (2027-2035)
Table 10.5: Market Size and CAGR of Various Application in the RoW Brucella Abortus Vaccine Market (2019-2026)
Table 10.6: Market Size and CAGR of Various Application in the RoW Brucella Abortus Vaccine Market (2027-2035)
Table 10.7: Trends and Forecast for the Middle Eastern Brucella Abortus Vaccine Market (2019-2035)
Table 10.8: Trends and Forecast for the South American Brucella Abortus Vaccine Market (2019-2035)
Table 10.9: Trends and Forecast for the African Brucella Abortus Vaccine Market (2019-2035)
Chapter 11
Table 11.1: Product Mapping of Brucella Abortus Vaccine Suppliers Based on Segments
Table 11.2: Operational Integration of Brucella Abortus Vaccine Manufacturers
Table 11.3: Rankings of Suppliers Based on Brucella Abortus Vaccine Revenue
Chapter 12
Table 12.1: New Product Launches by Major Brucella Abortus Vaccine Producers (2019-2026)
Table 12.2: Certification Acquired by Major Competitor in the Global Brucella Abortus Vaccine Market

Companies Mentioned

  • Zoetis
  • Ceva
  • Merck Animal Health
  • Biovet
  • Cavac
  • Jovac
  • Merial
  • Colorado Serum Company
  • Vecol
  • Tecnovax

Methodology

The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:

  • In-depth interviews of the major players in the market
  • Detailed secondary research from competitors’ financial statements and published data
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.

Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.

Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

 

Loading
LOADING...